METHODS	The sleep/HRQoL substudy enrolled 459 women with bothersome moderate to severe vasomotor symptoms who were randomized to BZA 20 mg/CE 0.45 mg , BZA 20 mg/CE 0.625 mg , BZA 20 mg , CE 0.45 mg/medroxyprogesterone acetate ( MPA ) 1.5 mg , or placebo for 1 year .\